<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Topical hemostatic agents for managing bleeding</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Topical hemostatic agents for managing bleeding</h1>
<div class="graphic"><div class="figure"><div class="ttl">Topical hemostatic agents for managing bleeding</div><div class="cntnt"><table cellspacing="0"><colgroup span="7" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent</td> <td class="subtitle1">Source</td> <td class="subtitle1">How supplied</td> <td class="subtitle1">Trade names in United States</td> <td class="subtitle1">Absorption time<sup>[1]</sup></td> <td class="subtitle1">Adverse effect*<sup>[2]</sup></td> <td class="subtitle1">Relative expense<sup>¶[1,3]</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="7">Physical agents</td> </tr> <tr> <td class="subtitle3_left" colspan="7">Wax-based</td> </tr> <tr> <td class="indent2">Bone wax</td> <td>Beeswax</td> <td>Stick form</td> <td>Not applicable</td> <td>Indefinite</td> <td>Impaired bone healing</td> <td>¢</td> </tr> <tr> <td class="indent2">Ostene (soluble copolymer implant material)</td> <td>Synthetic alkaline oxide copolymers</td> <td>Stick form</td> <td>Ostene</td> <td>48 hours</td> <td> </td> <td>¢</td> </tr> <tr> <td class="subtitle3_left" colspan="7">Dry matrix</td> </tr> <tr> <td class="indent2">Absorbable gelatin (gelatin matrix)</td> <td>Porcine</td> <td>Sponge, powder</td> <td>Gelfilm, Gelfoam, Surgifoam, Gelfoam hemostasis kit (also contains human thrombin)</td> <td>4 to 6 weeks</td> <td>Infection, abscess or granuloma formation, fibrosis, clot disruption if sponge is removed<sup>[1]</sup></td> <td>$</td> </tr> <tr> <td class="indent2">Oxidized regenerated cellulose</td> <td>Plant</td> <td>Mesh</td> <td>Surgicel (Nu-Knit, Fibrillar, SNoW)</td> <td>1 to 2 weeks<sup>Δ</sup></td> <td>Foreign body reaction, infection, adhesions<sup>[1]</sup></td> <td>$</td> </tr> <tr> <td class="indent2" rowspan="2">Microfibrillar collagen (collagen hemostat)</td> <td rowspan="2">Bovine</td> <td>Sheets</td> <td>Actifoam, Avitene (Ultrafoam), Endo Avitene, Instat MCH, Helistat Helitene, Syringe Avitene</td> <td rowspan="2">&gt;8 weeks</td> <td rowspan="2">Granuloma formation, allergenic</td> <td rowspan="2">$$</td> </tr> <tr> <td>Powder</td> <td>Avitene Flour</td> </tr> <tr> <td class="indent2">Microporous polysaccharide spheres (MPH)</td> <td>Synthetic</td> <td>Powder</td> <td>Arista AH</td> <td>24 to 48 hours</td> <td>Use of &gt;50 g can alter glucose load in patients with diabetes</td> <td>$</td> </tr> <tr> <td class="subtitle3_left" colspan="7">External agents</td> </tr> <tr> <td class="indent2">Chitosan</td> <td>Biodegradable complex carbohydrate derived from chitin</td> <td>Adhesive dressing</td> <td>HemCon bandage (Chitoflex)</td> <td>Not applicable</td> <td>Training needed to ensure proper application</td> <td>¢</td> </tr> <tr> <td class="indent2">Kaolin-impregnated sponge</td> <td>Aluminosilicate mineral</td> <td>Gauze sponge</td> <td>Quikclot</td> <td>Not applicable</td> <td>Possible clot disruption when sponge removed</td> <td>¢</td> </tr> <tr> <td class="indent2">Hemafiber</td> <td>Cellulose and silica</td> <td>Dressing, surgical pad, elastic wrap</td> <td>NuStat OTC, NuStat Trauma Pad XR, NuStat Flex</td> <td>Not applicable</td> <td>Possible clot disruption when pad removed</td> <td>$</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Biologically active agents</td> </tr> <tr> <td class="indent1" rowspan="3">Topical thrombin</td> <td>Bovine</td> <td rowspan="3">Liquid</td> <td>Thrombin-JMI</td> <td rowspan="3">Not applicable</td> <td rowspan="3"> <p>Intravascular application leads to thrombosis</p> Antibody formation against bovine thrombin can inhibit coagulation and prolong prothrombin time/INR</td> <td rowspan="3">$$</td> </tr> <tr> <td>Human</td> <td>Evithrom</td> </tr> <tr> <td>Recombinant human (rHuman)</td> <td>Recothrom</td> </tr> <tr> <td class="indent1" rowspan="3">Fibrin sealant (human fibrinogen and human thrombin)<sup>◊</sup></td> <td>Human</td> <td rowspan="2">Liquid</td> <td>Artiss, Tisseel (also contains synthetic aprotinin), Evicel, TachoSil, Evarrest, Vistaseal</td> <td rowspan="2">Immediate</td> <td rowspan="3">Potential exposure to blood-borne viruses</td> <td>$$$</td> </tr> <tr> <td>Human autologous</td> <td>CryoSeal Fibrin Sealant System Vitagel (autologous fibrinogen and bovine thrombin)</td> <td>Not available</td> </tr> <tr> <td>Human</td> <td>Powder (spray and direct application; for use with absorbable gelatin sponge)</td> <td>Raplixa</td> <td>(Refer to Absorbable gelatin sponge, above)</td> <td>Not available</td> </tr> <tr> <td class="indent1">Dry Fibrin Sealant Dressing (DFSD)<sup>§</sup></td> <td>Freeze-dried fibrinogen and thrombin applied to gauze substrate</td> <td>Dressing</td> <td>Not applicable</td> <td>Not applicable</td> <td> </td> <td>$$$$</td> </tr> <tr> <td class="indent1">Bovine albumin-glutaraldehyde tissue adhesive</td> <td>Bovine</td> <td>Liquid</td> <td>Bioglue</td> <td> </td> <td>Antibody formation against bovine thrombin can inhibit coagulation and prolong prothrombin time/INR</td> <td>$$$$</td> </tr> <tr> <td class="subtitle2_left" colspan="7">Combination preparations</td> </tr> <tr> <td class="indent1">Thrombin/gelatin</td> <td>Bovine or porcine</td> <td>Liquid</td> <td>Floseal (bovine), Surgiflo (porcine)</td> <td>6 to 8 weeks</td> <td>Antibody formation against bovine thrombin can inhibit coagulation and prolong prothrombin time/INR</td> <td>$$$</td> </tr> <tr> <td class="indent1">Thrombin/collagen</td> <td>Bovine</td> <td>Liquid</td> <td>Costasis</td> <td>4 weeks</td> <td>Antibody formation against bovine thrombin can inhibit coagulation and prolong prothrombin time/INR</td> <td>$$$</td> </tr> </tbody></table></div><div class="graphic_footnotes">INR: international normalized ratio.<br/>
	
	* Although rare, use of protein-containing topical hemostatics and fibrin sealants can be associated with severe hypersensitivity reactions and formation of antibodies; such reactions may be seen especially after repeated application.<br/>
	
	¶ The cost of topical hemostatics is highly variable in United States and subject to institutional contracting. Price range (US dollars): ¢: less than 50 dollars; $: 50 to 100 dollars; $$: 101 to 300 dollars; $$$: 301 to 500 dollars; $$$$: 501 to 750 dollars.<br/>
	
	Δ The low pH of the oxidized regenerated cellulose can inhibit proteases and elastase, which can delay resorption for more than two weeks.<br/>
<span class="lozenge">◊</span> Thrombin and fibrinogen concentrations vary. Fibrinogen concentrations are higher for commercial preparations. As an example, Tisseel, Evicel, and Vistaseal have fibrinogen concentrations of 70, 55 to 85, and 80 mg/mL, respectively, compared with 2.5 to 25 mg/mL for cryoprecipitate (unmanipulated). When rapid clot formation (5 to 10 seconds) is desired, thrombin concentrations of 500 to 1000 NIH units should be used (eg, Tisseel, 500 IU/mL; Evicel, 800 to 1200 IU/mL).<sup>[4,5,6]</sup><br/>
	
	§ Investigational.</div><div class="graphic_reference">References:
	<ol>
<li>Duenas-Garcia OF, Goldberg JM. Topical hemostatic agents in gynecologic surgery. Obstet Gynecol Surv 2008; 63:389.</li>
<li>Gabay M, Boucher B. An essential primer for understanding the role of topical hemostats, surgical sealants, and adhesives for maintaining hemostasis. Pharmacotherapy 2013; 33:935.</li>
<li>Hong YM, Loughlin KR. The use of hemostatic agents and sealants in urology. J Urol 2006; 176:2367.</li>
<li>TISSEEL VH Kit. Available at: <a href="https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm072968.pdf" target="_blank">https://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm072968.pdf</a> (Accessed on October 27, 2017).</li>
<li>EVICEL Fibrin Sealant. Available at: <a href="https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM270787.pdf" target="_blank">https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM270787.pdf</a> (Accessed on October 27, 2017).</li>
<li>VISTASEAL Fibrin Sealant. Available at: <a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8708417-2f74-4dfa-b6f9-ef88f902e0fc" target="_blank">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8708417-2f74-4dfa-b6f9-ef88f902e0fc</a> (Accessed on December 15, 2021).</li>
</ol></div><div id="graphicVersion">Graphic 71852 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
